Choudhary Narendra S, Saigal Sanjiv, Saraf Neeraj, Soin Arvinder S
Institute of Liver Transplantation and Regenerative Medicine, Gurugram, India.
J Clin Exp Hepatol. 2021 Jul-Aug;11(4):494-500. doi: 10.1016/j.jceh.2020.10.008. Epub 2020 Oct 24.
Recipients of liver transplantation (LT) remain at higher risk (adjusted for other risk factors) of de novo malignancies (DNMs). The higher risk can be attributed to the effect of immunosuppression and patient-related risk factors (age, tobacco, alcohol, etiology of liver disease). DNMs are an important cause of late mortality in liver transplant recipients. The pattern (type) of posttransplant malignancies reflects pattern in local population. The common types include skin cancers, solid organ malignancies, and post-transplant lymphoproliferative disorders. Counseling of patients about risk factors and surveillance protocols may help in the prevention and diagnosis at early stage. We also discuss the results of LT in patients with a history of extrahepatic malignancy in the pretransplant period.
肝移植（LT）受者发生新发恶性肿瘤（DNMs）的风险（经其他风险因素校正后）仍然较高。这种较高风险可归因于免疫抑制的影响以及患者相关风险因素（年龄、烟草、酒精、肝脏疾病病因）。DNMs是肝移植受者晚期死亡的重要原因。移植后恶性肿瘤的类型反映了当地人群的情况。常见类型包括皮肤癌、实体器官恶性肿瘤和移植后淋巴细胞增生性疾病。就风险因素和监测方案对患者进行咨询可能有助于早期预防和诊断。我们还讨论了移植前有肝外恶性肿瘤病史患者的肝移植结果。
